Business Description
Vaxil Bio Ltd
NAICS : 325410
SIC : 3741
ISIN : CA92243L1076
Compare
Compare
Traded in other countries / regions
VXL.CanadaVXLLF.USA IPO Date
2016-03-14Description
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33.3 | |||||
3-Year FCF Growth Rate | 40.7 | |||||
3-Year Book Growth Rate | -6.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.68 | |||||
9-Day RSI | 24.26 | |||||
14-Day RSI | 32.27 | |||||
3-1 Month Momentum % | -78.95 | |||||
6-1 Month Momentum % | -72.38 | |||||
12-1 Month Momentum % | -77.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.92 | |||||
Quick Ratio | 16.92 | |||||
Cash Ratio | 14.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | 52.43 | |||||
ROA % | 51.38 | |||||
ROIC % | -49.78 | |||||
ROC (Joel Greenblatt) % | -1432.26 | |||||
ROCE % | -24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.97 | |||||
PE Ratio without NRI | 1 | |||||
PEG Ratio | 0.02 | |||||
PB Ratio | 0.57 | |||||
Price-to-Tangible-Book | 0.55 | |||||
EV-to-EBIT | -0.86 | |||||
EV-to-EBITDA | -0.86 | |||||
EV-to-FCF | -0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.04 | |||||
Price-to-Graham-Number | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 2.21 | |||||
Earnings Yield (Greenblatt) % | -116.28 | |||||
FCF Yield % | -35.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:VXLLF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxil Bio Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0.134 | ||
| Beta | 3.2093 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.71 | ||
| Volatility % | 411.84 | ||
| 14-Day RSI | 32.27 | ||
| 14-Day ATR ($) | 0.001986 | ||
| 20-Day SMA ($) | 0.0221 | ||
| 12-1 Month Momentum % | -77.9 | ||
| 52-Week Range ($) | 0.0021 - 0.5 | ||
| Shares Outstanding (Mil) | 3.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxil Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxil Bio Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.02:1 Stock Split | 2025-05-15 | 0.26 (+0.00%) |
Show
Entries
Vaxil Bio Ltd Frequently Asked Questions
What is Vaxil Bio Ltd(VXLLF)'s stock price today?
The current price of VXLLF is $0.02. The 52 week high of VXLLF is $0.50 and 52 week low is $0.00.
When is next earnings date of Vaxil Bio Ltd(VXLLF)?
The next earnings date of Vaxil Bio Ltd(VXLLF) is .
Does Vaxil Bio Ltd(VXLLF) pay dividends? If so, how much?
Vaxil Bio Ltd(VXLLF) does not pay dividend.
Guru Commentaries on OTCPK:VXLLF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vaxil Bio Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers